Objective: The aim of this study was to identify causative variants associated with Allan-Herndon-Dudley syndrome (AHDS) in two unrelated Chinese families, and to determine their potential pathogenicity. We also summarized the core clinical symptoms of AHDS by reviewing the related literature.

Methods: Genomic DNA was isolated from the peripheral blood of AHDS patients and their family members. Whole exome sequencing (WES) was performed on the proband from each family to identify the candidate variants. Subsequently, Sanger sequencing was used to verify the identified candidate variants and to assess co-segregation among the available family members. In silico prediction combined with 3D protein modeling was conducted to predict the functional effects of the variants on the encoded protein.

Results: Two novel hemizygous variants of SLC16A2, c.1111_1112insGTCTTGT (Gly375fs*6) and c.942delA (Val315fs*28), were detected in two patients. We compared the clinical symptoms of the patients with all patients with AHDS reported in China and those reported in the literature. While both our patients presented symptoms mostly consistent with AHDS, Patient 1 had no abnormal brain structure and thyroid function, and yet showed other symptoms including lactic aciduria, conjunctival hyperemia, vomiting, laryngeal stridor, low immunoglobulin and iron levels.

Conclusions: This study expands the mutation spectrum of AHDS and has clinical value for variant-based prenatal and postnatal screening for this condition. Doctors often have difficulty identifying AHDS by using clinical symptoms. WES can help to identify specific disorder when diagnosis cannot be made based on symptoms alone.

Keywords
Allan-Herndon-Dudley syndrome, SLC16A2, MCT8, thyroid hormone transporter, X-linked mental retardation
Introduction

Allan-Herndon-Dudley syndrome (AHDS) was first reported by Allan in 1944 (1). In 2004, it was confirmed that AHDS is caused by variants in the SLC16A2 gene which is located in the Xq13.2 region of chromosome (chrX:73,641,328–73,753,751 GRCh37/hg19) (2, 3). The SLC16A2 gene spans 112,424 bases, contains six exons and five introns, and is translated into a protein consisting of 399 amino acids. Although the incidence of AHDS is currently unknown, the number of reported cases in the literature so far suggests that the syndrome is more common than we previously thought.

AHDS is the result of loss of function of MCT8, which is the protein product of the SLC16A2 gene. MCT8 is an integral membrane protein that acts as a thyroid hormone transporter. It facilitates the cellular importation of T2 (diodothyronine), T3 (triiodothyronine), T4 (thyroxine) and rT3 (reverse triiodothyronine), and it plays a critical role in the development of the nervous system (4). MCT8 is also thought to play a key role in the neuronal uptake of thyroid hormone by T3 and endothelial cells allowing the hormone to cross blood-brain barrier. MCT8 deficiency can result in a decrease of T3 to nuclear T3 receptors. Therefore, the T3 reduction in brain cells may contribute to a severe neurodevelopmental deficit in males with AHDS (5, 6). Most pathogenic variants of AHDS result in either reduced activity or complete inactivation of MCT8. However, variants that result in incomplete inactivation of the protein can lead to a milder phenotype (7). Here, we report two novel frameshift variants of SLC16A2 which were revealed by whole exome sequencing (WES) in two Chinese boys. These findings will help to further expand the mutation spectrum and provide potential novel clinical features of AHDS.

Materials and methods

Next generation sequencing

Both patients were examined by using WES. Genomic DNA samples were collected and sequence libraries were constructed using the Agilent Sure Select Human Whole Exome V2 Kit (Agilent Technologies, Santa Clara, CA). The prepared libraries were sequenced using the HiSeq2500 System (Illumina, San Diego, CA). Reads obtained from the BWA software package (v. 0.7.15) were mapped with the human reference genome (GRCh37/hg19). Variant calling and variant annotation were performed by using the Genome Analysis Toolkit (GATK) and further variant annotation and prioritization were performed by using the TGex software (LifeMap Sciences, Inc.v5.7).

Sanger sequencing confirmation

A 2.5 ml of venous blood sample was taken from all the family members and Sanger sequencing was performed to confirm the presence of the variant. The following primers designed by primer3 were used: 5′-TGCTGSGGGGA TAAGATCAAG-3′ and 5′-GCCCACTCCTGATTCCTCA-3′ for c.942delA (Val315fs*28) and 5′-CTCCCTTTTCT CACCCTGTT-3′ and 5′-GCCCTCAGAATCCCTCACTCA-3′ for c.1111_1112insGTCTGTG (Gly375fs*6).

Bioinformatic analysis and verification of observations

The bioinformatics tools SIFT (http://sift.jcvi.org/), Mutation Taster software (http://www.mutationtaster.org/), Provean (http://provean.jcvi.org/seq_submit.php), and NMDEscPredictor (https://nmdprediction.shinyapps.io/nmdescpredictor/) were used to predict the impact of the variants on protein function. The protein 3D structures of SLC16A2 were generated by using the Swiss-Model server (https://swissmodel.expasy.org/) and the ACMG/AMP variant classification guidelines were used for variant classification (8).

Results

Clinical data

Proband 1 was a boy admitted to our hospital at the age of one month with no response to sound, lack of movements, poor facial expression, unsteady gaze, hypertonia, laryngeal stridor, feeding difficulties and neonatal hypothyroidism. The boy had a twin brother. Both were born at 37 weeks of gestation to healthy, non-consanguineous parents. He was a product of a breech birth with a weight and length of 2.68 kg and 50 cm, respectively. No neonatal asphyxia was observed during the delivery. The Apgar scores were excellent (Apgar score: 10/10/10). This boy showed poor sucking and had difficulty with swallowing. Meanwhile, he had frequent respiratory infections as an infant. His mother suffered from gestational diabetes and hypothyroidism during her pregnancy.

Physical examination of the patient’s length (52 cm), weight (3.04 kg) and head circumference (33 cm) were collected. His physical examination revealed malnutrition, apathy, slow response, ankle clonus, muscle hyperirritability, neck muscle weakness, conjunctival hyperemia and laryngeal stridor. His hearing, vision and skeletal system were normal. A routine ECG showed sinus tachycardia.

Ultrasonography of the liver, reproductive system and kidneys were normal. Magnetic resonance imaging (MRI) and neonatal echocardiography were also normal (Figures 1D,
He was treated for infection in hospital and discharged thereafter. At 5 months of age, the boy presented with worsening laryngeal stridor symptoms with sputum production and vomiting. He continued to present with failure to thrive and limb hypertonia with dull eyes, poor adaptability and gross motor development.

**D1–D3**). The clinical features of the probands with Allan-Herndon-Dudley Syndrome. (A–A-1) show the phenotypic characteristics of patient 1: fixed facial expression and neck muscle weakness. (B–B-2) show the phenotypic characteristics of patient 2: fixed facial expression and muscle weakness. (C–C-4) show the facial features and muscle weakness and special posture of patient 2’s elder brother. (D–D3) show the cranial MRIs of patient 1 (normal). (E–E3) are patient 2 cranial MRIs. (E,E–E3) represent T1WI, T2WI, a high b-value DWI and ADC images, respectively. The results reveal a patchy long T1 and a long T2 signal shadow in the left mid-cerebellar peduncle, with a slightly high signal on high b-value DWI and a slightly low signal on ADC images.
The main findings biochemical and metabolic tests included euthyroidism (T3: 3.15 nmol/L, normal range 1.23–4.22 nmol/L, T4: 80.97 nmol/L, normal range 69.6–219 nmol/L, free T3: 6.71 pmol/L, normal range 3.0–9.28 pmol/L, free T4: 12.19 pmol/L, normal range 11.5–28.3 pmol/L, Thyrotropin (TSH): 3.48 uIU/ml normal range 0.72–11 uIU/ml); elevated white blood cell (12.80*10^9/L, normal range 4.00–10.00*10^9/L), lymphocyte percentage (149.00%, normal range 20%–40%) and lactic acid (4.50 mmol/L, normal range 0.50–1.60 mmol/L) and reduced iron level (9.00 μg/dl, normal range 11–30 μg/dl). The total serum protein was 58.00 g/L (normal range 60.00–80.00 g/L), albumin 42.30 g/L (normal range 35.00–55.00 g/L), immunoglobulin G 2.62 g/L (normal range 7.00–16.00 g/L), immunoglobulin A 0.18 g/L (normal range 0.70–3.30 g/L), and immunoglobulin M 0.38 g/L (normal range 0.50–2.20 g/L). His twin brother had similar symptoms and his elder sister had a normal phenotype.

Patient 2 was a boy who came to our hospital at 6 months of age due to motor retardation. A physical examination revealed his height (66.2 cm) and weight (8.2 kg) were normal. He had neck muscle weakness, limb hypertonia, head retroflexion, microcephaly (39.5 cm, <-2 SD), epilepsy, muscle hyperirritability and poor motor coordination. T2-weighted MRI imaging (T2WI) revealed a low signal intensity in the posterior limbs of the internal capsules (Figures 1E,E1–E3). Thyroid function tests revealed abnormal levels of T3 (5.78 nmol/L, normal range 1.32–4.07 nmol/L), T4 (53.32 nmol/L, normal range 73–206 nmol/L), free T3 (15.72 nmol/L, normal range 3.3–8.95 nmol/L) and free T4 (6.73 nmol/L, normal range 11.9–25.6 nmol/L). His mother’s thyroid function test results suggested a decrease in T4: 3.49 (normal range 5.00–13.00) pg/dl). The proband’s elder brother had similar but more severe symptoms (Figures 1C, C-1–C-4). He presented with microcephaly, epilepsy, profound intellectual disability and severe cerebral palsy. His thyroid function was also abnormal (T3: 2.78 nmol/L, T4: 4.39 ug/dl, free T3: 9.23 pmol/L and free T4:12.02 pmol/L). A brain CT scan at the age of 4 months reported no significant abnormality (Figure 1 for characteristics of the patients).

**Genetic testing**

We identified a hemizygous variant c.942delA (Val315fs*28) of SLC16A2 (NM_006517.4, ChrX:73,744,559 in exon 3) in patient 1 and c.1111_1112insGTCTTGT (Gly375fs*6) (NM_006517.4, ChrX:73,745,669 in exon 4) in patient 2 by using WES.

Sanger sequencing revealed that the c.942delA (Val315fs*28) and c.1111_1112insGTCTTGT (Gly375fs*6) variants were inherited from the mother of patients 1 and 2, respectively (Figure 2). Four in silico tools were used to predict the impact of the two novel variants (Figure 3B). Predictive software suggested that c.942delA (Val315fs*28) and c.1111_1112insGTCTTGT (Gly375fs*6) were harmful variants. The Swiss-Model software was used to predict the three-dimensional structure of the wild-type (WT) and variant of the SLC16A2 proteins. By comparison, it was clear that variants had altered the protein length and overall shape of the SLC16A2 protein. Variants can cause a frameshift which results in premature truncation of the protein that is likely to cause major changes in protein activity. The protein products are usually more unstable and are easily degraded. This is demonstrated diagrammatically in Figures 3A,A-1,A-2. Thus, both variants can be classified as pathogenic with supporting evidence such as PVS1 + PM2-supporting + PP4 + PP1. According to the Orphanet (www.orphadata.org), at least 132 families with 320 affected individuals had been reported worldwide. We searched the databases (OMIM, Wanfang, CNKI and PubMed) for reported Chinese AHDS patients. To date only 9 families with AHDS have been reported in China. An extensive literature review was conducted (Table 1).

**Discussion**

AHDS is a disorder of brain development that leads to moderate to severe intellectual disability and problems with movement. The SLC16A2 gene is the only known causal gene. The gene is widely expressed in tissues and it may play a key role in the development of the central nervous system (9, 10). In males, loss-of-function variants in this gene are associated with psychomotor retardation, but in females there is no neurological deficit, and the thyroid-deficiency phenotype is mild (11). Pathogenic variants in SLC16A2 have been found in diverse populations around the world (12–14).

Two novel variants are described in this study, c.1111_1112insGTCTTGT (Gly375fs*6) and c.942delA (Val315fs*28). In addition, we summarized all the reported mutants that cause AHDS syndrome in Chinese patients (Figure 4). The variants reported in this study are all frameshift variants. Both resulted in premature stop codons that could act as nonsense-mediated mRNA decay (PVS1). Furthermore, neither were found to be present in controls, the 1,000 Genome Project and the Exome Sequencing Project (PM2-supporting). Rare SNPs have very broad and deleterious effects on phenotypes when compared to the weak effects of common SNPs (15). The clinical presentation of all the affected individuals in these families are consistent with the symptoms of AHDS (PP4), and the genotype co-segregated with the phenotype in at least one family tested (PP1). Thus both novel variants can be classified as pathogenic.

The clinical presentations of AHDS includes neurologic findings, pyramidal and extrapyramidal findings, seizures and dysthyroidism (16, 17). There are considerable inter- and intra-familial differences in phenotypes. In severe cases, the
patient will be unable to walk or speak. Our two patients exhibited many of these clinical features, including hypotonia, feeding difficulties, dystonia and choreoathetosis. We have compiled the clinical phenotypes, laboratory tests results and molecular characteristics of the 9 cases previously reported in China (Table 1) (18–22). We compared the clinical characteristics of Chinese patients with those reported in the literature and found that the most common clinical manifestations are psychomotor retardation (Chinese cohort: literature, 100:100%), motor delay (Chinese cohort: literature, 100:100%) muscular hypotonia (Chinese cohort: literature, 100:74%–100%) and muscle hyperirritability (Chinese cohort: literature, 100:70.8%–94%). The above symptoms are the core clinical symptoms of AHDS syndrome. Other symptoms include low weight (Chinese cohort: literature, 80.0:37–66.6%), microcephaly (Chinese cohort: literature, 100:10–33.3%), sinus tachycardia (Chinese cohort: literature, 100.0:1.4), abnormal thyroid function (Chinese cohort: literature, 90.91:27.9–66.6%) and abnormal brain MRIs (Chinese cohort: literature, 72.73:33.1–79.1%). Although reported in several patients (Table 1, P2–3), delayed myelination is not a consistent feature necessarily associated with neurological symptoms of AHDS.

We should also consider the possibility of AHDS in males having typical thyroid and neurological symptoms. Phenotypic severity is generally thought to be related to the residual transport function of the MCT8 protein. Some pathogenic missense variants and in-frame SNP deletions are associated
with milder clinical phenotypes (6). Some patients die early on from recurrent infections and/or aspiration pneumonia (23). Currently, only one case of a female patient has been reported, the rest being males. Most heterozygous women have no neurological symptoms, but thyroid function tests may be mildly abnormal, possibly due to altered X chromosome inactivation (24).

In this study, the percentage of abnormal maternal thyroid function was only 37.50%. Some researchers believe that a thyroid hormone level with a free T3/T4 ratio above 0.75 is helpful in diagnosing patients. However, in this study, only 67% (6/9) of patients fulfilled this condition (24). It can be seen that the method has limited diagnostic value in detecting AHDS. By itself, it is not sufficient as a diagnostic indicator but it can guide the molecular diagnosis. All variants reported in China have been assessed as pathogenic or likely pathogenic variants according to the ACMG guidelines. Among these, the variants were mainly inherited from the mother, and the de novo rate is 27.27%.

At present, there is no report of incomplete penetrance of AHDS, but there was heterogeneity in presentation of clinical severity. However, mutations in the SLC16A2 gene can lead to differences in MTC8 transport function and thus differences in neurological symptoms in the patients (7, 25). Our patients presented with similar facial features, such as a long face, thick and tented upper lip, open mouth, of which these may have been due to prenatal and infantile hypotonia. In addition, the patients in this study also exhibited some heterogeneous clinical presentation clinical symptoms, including lacticaciduria, hyperkalemia, conjunctival hyperemia and laryngeal stridor. Low immunoglobulin and iron levels and vomiting are also potential novel clinical features of the disease. These symptoms may be related to the novel variants, or they may be non-specific. Due to the young age of the patients in this study, some neurological symptoms may yet manifest themselves. The lacticaciduria and low immunoglobulin levels seen may be associated with infection and malnutrition, but this will need to be confirmed by further studies involving more cases. Unfortunately, due financial difficulties, the family was unwilling to proceed with further tests and examinations. However, we will continue to follow-up these families in an effort to further improve the relevant data regarding AHDS.

The heterogeneous manifestations of AHDS make it difficult for clinicians to diagnose the disease based on the clinical presentation alone. Other disorders with X-linked or autosomal recessive inheritance patterns such as MECP2 duplication syndrome, X-linked progressive cerebellar ataxia, Pelizaeus-Merzbacher disease and non-goitrous congenital hypothyroidism 6 could exhibit overlapping features. These include hypotonia, progressive spasticity, absent speech, hypomyelination, abnormal thyroid hormones and severe intellectual disability and they are all candidates for differential diagnosis.

AHDS is a rare disorder of brain development. The presentation of abnormal relative concentrations of three
| TABLE 1 Clinical characteristics of 11 patients with AHDS syndrome in China. |
|------------------------------------------|
| **Age**  | 8.75 year | 0.75 year | 0.75 year | 1.25 year | 0.75 year | 0.67 year | 1 year | 1 year | 0.33 year | 0.08 year | 0.5 year |
| **Sex**  | M | M | M | M | M | M | M | M | M | M | M |
| **Full-term infant** | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ |
| **Family history** | – | – | – | – | – | – | – | – | – | – |
| **Low Weight (kg)** | 17.2 (<−3SD) | 7.6 (<−1SD∼−2SD) | 9.5 (<−1SD) | 8 (<−1SD∼−2SD) | 8.8 (<−1SD) | 7 (<−2SD) | NA | NA | 9.5 (<−1SD) | 8 (<−1SD∼−2SD) | 8.8 (<−1SD) | 7 (<−2SD) | 3.04 kg (<−3SD) | 8.2 kg (Normal) | 80.00% | 37%–66.6% |
| **Abnormal head circumferences (cm)** | NA | NA | NA | NA | NA | 44 cm (<−1SD) | 45 cm (<−2SD) | NA | NA | 33 cm (<−2SD) | 39.5 cm (<−2SD) | 100.00% | 10%–33.3% |
| **Motor delay** | + | + | + | + | + | + | + | + | + | + | + |
| **Psychomotor retardation** | + | + | + | + | + | + | + | + | + | + | + |
| **Speech** | No speech | No speech | No speech | No speech | No speech | No speech | No speech | No speech | No speech | No speech |
| **Muscular hypotonia** | + | + | + | + | + | + | + | + | + | + |
| **Muscle hyperirritability** | + | + | + | + | + | + | + | + | + | + |
| **Babinski’s sign** | + | + | + | + | + | – | NA | NA | – | + | 75.00% |
| **Abnormal Cranial MRI result** | – | – | Demyelination (5 m) | Demyelination (7 m) | cerebra gap widened, Delayed myelination and mild cortical atrophy | delayed myelination and mild cortical atrophy | local changes in the white matter around the posterior corners of the bilateral ventricles | cerebra gap widened (bilateral frontoparietal); Delayed myelination (anterior limb of internal capsule); Pachygyria (bifrontal lobes) | – | a patchy long T1 and long T2 signal shadow in the left mid-cerebellar peduncle, with a slightly high signal on high b-value DWI and a slightly low signal on ADC. |
| **Sinus tachycardia** | + | + | + | + | + | NA | NA | NA | + | + | + |
| **Thyroid hormone levels** | TT3: (−) | TT3: (−) | TT3: (1) | TT3: (1) | TT3: (1) | TT3: (1) | TT3: (1) | TT3: NA | TT3: NA | TT3: NA | TT3: (−) |
| | FT3: (1) | FT3: (1) | FT3: (1) | FT3: (1) | FT3: (1) | FT3: (1) | FT3: NA | FT3: (1) | FT3: (1) | FT3: (1) | FT3: (1) |
| | FT4: (1) | FT4: (1) | FT4: (1) | FT4: (1) | FT4: (1) | FT4: (1) | FT4: (1) | TT4: NA | TT4: NA | TT4: NA | TT4: (1) |
| | FT4: (1) | FT4: (1) | FT4: (1) | FT4: (1) | FT4: (1) | FT4: (1) | FT4: (1) | FT4: (1) | FT4: (1) | FT4: (1) | FT4: (1) |
| | TSH: (−) | TSH: (−) | TSH: (−) | TSH: (−) | TSH: (−) | TSH: (−) | TSH: (−) | TSH: NA | TSH: NA | TSH: NA | TSH: (−) |

(continued)
| Variation types | missense | missense | missense | Frameshift | Frameshift | Splicing mutation | Splicing mutation | Splicing mutation | Frameshift | Frameshift |
|-----------------|---------|---------|---------|-----------|-----------|------------------|------------------|------------------|-----------|-----------|
| Variations      | c.916C>T (p. Q306*) | c.916C>T (p. Q306*) | c.695-699delATGGT (p. N232Sfs*7) | c.431-1 G>C | c.431-2 A>G | c.3028 + 1G>A | T195delC (p. W155Glufs*) | V315delG (p. W316fs*) | c.942del A (p. V315fs*28) | 1111_1112insGTCTTGTT (p. G375fs*4) | NA | NA |
| Genetic origin  | Mo (Mother) | Mo | De novo | De novo | Mo | Mo | Mo | Mo | Mo | De:Mo = 1.2.67 | De:Mo = 1.2.43 |

| Maternal Thyroid Function |
|---------------------------|
| NA | NA | NA | NA | NA | NA |

| Others |
|--------|
| Long face, Narrow forehead, Open mouth, Thick vermilion border, Tent upper lip vermilion |
| Long face, Narrow forehead, Open mouth, Thick vermilion border, Tent upper lip vermilion |
| Long face, Cupped ear, Esotropia; Pneumonia; Scoliosis; Cryptorchidism; Dyspnea; Hyperbilirubinemia, G6PD |
| Long face, Cupped ear, Esotropia; Pneumonia; Lactic aciduria; Conjunctival hyperemia; Vomiting; Poor appetite; Laryngeal stridor; Malnutrition; aplasty; low immunoglobulin and iron levels |

| Variation types | missense | missense | missense | Frameshift | Frameshift | Splicing mutation | Splicing mutation | Splicing mutation | Frameshift | Frameshift |
|-----------------|---------|---------|---------|-----------|-----------|------------------|------------------|------------------|-----------|-----------|
| Variations      | c.916C>T (p. Q306*) | c.916C>T (p. Q306*) | c.695-699delATGGT (p. N232Sfs*7) | c.431-1 G>C | c.431-2 A>G | c.3028 + 1G>A | T195delC (p. W155Glufs*) | V315delG (p. W316fs*) | c.942del A (p. V315fs*28) | 1111_1112insGTCTTGTT (p. G375fs*4) | NA | NA |
| Genetic origin  | Mo (Mother) | Mo | De novo | De novo | Mo | Mo | Mo | Mo | Mo | De:Mo = 1.2.67 | De:Mo = 1.2.43 |
circulating thyronine molecules along with severe neurological
abnormalities should provide diagnostic clues of AHDS. WES
is a valuable test for identifying the causal genes in these
patients. According to the literature, the majority of patients
were diagnosed with AHDS when there were either clinical
symptoms combined with WES or WES alone. Currently,
there is no effective treatment for AHDS. Observational
studies have shown that 3,3′,5-triiodothyroacetic acid
(TRIAC) can restore some thyroid functions, and thus
provides a possible treatment option (26).

Conclusions

In this study, two novel pathogenic variants in the SLC16A2
gene were identified in two Chinese patients who exhibited
symptoms of neurodevelopmental delay, extrapyramidal
dystonia, chorea and tardive dyskinesia), and pyramidal
(spasticity). The variants described in this study expand the
phenotypic spectrum of patients with different ethnic
backgrounds, which are valuable for the genetic diagnosis and
future variant-based screening for AHDS.

Data availability statement

The datasets presented in this study can be found in online
repositories. The names of the repository/repositories
and accession number(s) can be found in the article/
Supplementary Material.

Ethics statement

Written informed consent was obtained from the
individual(s), and minor(s)’ legal guardian/next of kin, for the
publication of any potentially identifiable images or data
included in this article.

Author contributions

ZQ, YQ and JSL: wrote the manuscript and analyzed the
data and performed the literature search. ZQ: prepared
the figures. SY: processed the data. ZLQ and ZXZ: collected
the blood samples and analyzed the data. All authors
contributed to the article and approved the submitted version.

Funding

This study was supported by the Guangxi Zhuang
Region Health Department (grant no. Z20190311 and
Z-A20220256).

Acknowledgments

We sincerely thank all the family members for their support
during this study. The authors would like to thank Professor
Yiping Shen for valuable suggestions and helping to edit the
manuscript. We also thank Dev Sooranna of Imperial College
London for editing the manuscript.
Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2022.1050023/full#supplementary-material.

References

1. Masnada S, Sarret C, Antonello CE, Fadhilah A, Krude H, Mura E, et al. Movement disorders in MCT8 deficiency/Allan-Herndon-Dudley syndrome. Mol Genet Metab. (2022) 135:109–13. doi: 10.1016/j.ymgme.2021.12.003
2. Dumitrescu AM, Liao XH, Best TB, Brockmann K, Refetoff S. A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. Am J Hum Genet. (2004) 74:168–75. doi: 10.1086/389099
3. Friesema EC, Grueters A, Biebmann H, Krude H, von Moers A, Reeser M, et al. Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation. Lancet. (2004) 364:1435–7. doi: 10.1016/S0140-6736(04)17226-7
4. van Geest FS, Gunhanlar N, Groeneweg S, Visser WE. Monocarboxylate transporter 8 deficiency: from pathophysiological understanding to therapy development. Front Endocrinol. (2021) 12:723750. doi: 10.3389/fendo.2021.723750
5. Vancamp P, Demeuninx BA, Renaud S. Monocarboxylate transporter 8 deficiency: delayed or permanent hypothyreomaly? Front Endocrinol. (2020) 11.283. doi: 10.3389/fendo.2020.00283
6. Masnada S, Groeneweg S, Saletti V, Chiapparini L, Castellotti B, Salsano E, et al. Novel mutations in SLC16A2 associated with a less severe phenotype of MCT8 deficiency. Metab Brain Dis. (2019) 34:1565–75. doi: 10.1007/s11011-019-00464-7
7. Friesema EC, Jansen J, Heuer H, Trajkovic M, Bauer K, Visser TJ. Mechanisms of disease: psychomotor retardation and high T3 levels caused by mutations in monocarboxylate transporter 8. Nat Clin Pract Endocrinol Metab. (2006) 2:512–23. doi: 10.1038/ncpendmet0162
8. Li Q, Wang K. Intervar: clinical interpretation of genetic variants by the 2015 ACMG-AMP guidelines. Am J Hum Genet. (2017) 100:267–80. doi: 10.1016/j.ajhg.2017.01.004
9. Vatine GD, Shelest O, Barriga BK, Ofan R, Rubinski T, Mattis VR, et al. Oligodendrocyte progenitor cell maturation is dependent on dual function of MCT8 in the transport of thyroid hormone across brain barriers and the plasma membrane. Glia. (2021) 69:2146–59. doi: 10.1002/glia.24014
10. Fellmle MA, Jones RS, Rodriguez-Cruz V, Follman KE, Morris ME. Monocarboxylate transporters (SLC16): function, regulation, and role in health and disease. Pharmacol Rev. (2020) 72:466–85. doi: 10.1124/pr.119.018762
11. Dumitrescu AM, Liao XH, Weiss RE, Millen K, Refetoff S. Tissue-specific thyroid hormone deprivation and excess in monocarboxylate transporter (mct) 8-deficient mice. Endocrinology. (2006) 147:4036–43. doi: 10.1210/en.2006-0390
12. Novara F, Groeneweg S, Freti E, Estemne M, Reho P, Mattricki S, et al. Clinical and molecular characteristics of SLC16A2 (MCT8) mutations in three families with the Allan-Herndon-Dudley syndrome. Hum Mutat. (2017) 38:260–4. doi: 10.1002/humu.23140
13. Islam MS, Namba N, Ohata Y, Fujiwara M, Nakano C, Takeyari S, et al. Functional analysis of monocarboxylate transporter 8 mutations in Japanese Allan-Herndon-Dudley syndrome patients. Endocr J. (2019) 66:19–29. doi: 10.1507/endocrj.EJ18-0251
14. Grijota-Martinez C, Baruz-Lopez S, Gomez-Andres D, Guadano-Ferraz A. MCT8 Deficiency: the road to therapies for a rare disease. Front Neuosci. (2020) 14:380. doi: 10.3389/fnins.2020.00380
15. Bomba I, Walter K, Soranzo N. The impact of rare and low-frequency genetic variants in common disease. Genome Biol. (2017) 18:77. doi: 10.1186/s13059-017-1212-4
16. Besheshi R, Aprile J, Lee C. Allan-Herndon-Dudley syndrome: a novel pathogenic variant of the SLC16A2 gene. Cureus. (2022) 14:e21771. doi: 10.7759/cureus.21771
17. Noorain S, Hamzehlou S, Rabbani A, Sotoudeh A, Pour Rostami K, Savad S. The role of thyroid function tests in diagnosing Allan-Herndon-Dudley syndrome revisited: a novel Iran-based mutation. Basic Clin Neurosci. (2021) 12:563–8. doi: 10.3259/bcn.2021.1924.1
18. Wang J, Zhang Q, Bao X, Chen Y, Yu S. Clinical and genetic features of five patients with Allan-Herndon-Dudley syndrome. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. (2018) 35:484–8. doi: 10.3760/cma.j.issn.1006-9406.2018.04.005
19. Tang YL, Peng J, Xiong J, Pang N, Wu LW, Yang HY, et al. A family with Allan-Herndon-Dudley syndrome due to SLC16A2 gene mutation. Zhonghua Yi Ke Za Zhi. (2018) 56:829–34. doi: 10.3760/cma.j.issn.0578-1310.2018.11.008
20. Chen X, Liu L, Zeng C. A novel variant in SLC16A2 associated with typical Allan-Herndon-Dudley syndrome: a case report. BMC Pediatr. (2022) 22:180. doi: 10.1186/s12887-022-03259-5
21. Wang A, Xu J, Yuan F, Wang Y, Wang S, Wang C, et al. Generation of an induced pluripotent stem cell line (SHCDNi003-A) from a one-year-old Chinese Han infant with Allan-Herndon-Dudley syndrome. Stem Cell Res. (2020) 46:101877. doi: 10.1016/j.scr.2020.101877
22. Qianfang ZF, Qingyang CUI. Allan-Herndon-Dudley syndrome caused by a novel mutation of SLC16A2 gene: a case report and literature review. J Clin Pediatr. (2020) 38:953–6. doi: 10.3969/j.issn.1000-3606.2020.12.017
23. Remerand G, Baequell-Tanguy O, Tonduti D, Touraine R, Rodriguez D, Cure A, et al. Expanding the phenotypic spectrum of Allan-Herndon-Dudley syndrome in patients with SLC16A2 mutations. Dev Med Child Neurol. (2019) 71:1439–47. doi: 10.1111/dmcn.14332
24. Quesa-Pedrosa JF, Garzon-Lorenzo L, Leonza-Rosales JM, Gomez-Rodriguez MJ, Sanchez-Calvin MT, Palma-Milla C, et al. First female with Allan-Herndon-Dudley syndrome and partial deletion of X-inactivation center. Neurogenetics. (2021) 22:343–6. doi: 10.1007/s10048-021-00660-7
25. Armour CM, Kersseboom S, Toon G, Visser TJ. Further insights into the Allan-Herndon-Dudley syndrome: clinical and functional characterization of a novel MCT8 mutation. PLoS One. (2015) 10(10):e0139343. doi: 10.1371/journal. pone.0139343
26. Kersseboom S, Horn S, Visser WE, Chen J, Friesema EC, Vauz-Barriere C, et al. In vitro and mouse studies supporting therapeutic utility of triiodothyroacetic acid in MCT8 deficiency. Mol Endocrinol. (2014) 28:1961–70. doi: 10.1210/me.2014-1135